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Abstract
The genetic adaptation of pathogens in host tissue plays a key role in the establishment of chronic infections. While whole
genome sequencing has opened up the analysis of genetic changes occurring during long-term infections, the
identification and characterization of adaptive traits is often obscured by a lack of knowledge of the underlying molecular
processes. Our research addresses the role of Pseudomonas aeruginosa small colony variant (SCV) morphotypes in long-term
infections. In the lungs of cystic fibrosis patients, the appearance of SCVs correlates with a prolonged persistence of
infection and poor lung function. Formation of P. aeruginosa SCVs is linked to increased levels of the second messenger c-di-
GMP. Our previous work identified the YfiBNR system as a key regulator of the SCV phenotype. The effector of this tripartite
signaling module is the membrane bound diguanylate cyclase YfiN. Through a combination of genetic and biochemical
analyses we first outline the mechanistic principles of YfiN regulation in detail. In particular, we identify a number of
activating mutations in all three components of the Yfi regulatory system. YfiBNR is shown to function via tightly controlled
competition between allosteric binding sites on the three Yfi proteins; a novel regulatory mechanism that is apparently
widespread among periplasmic signaling systems in bacteria. We then show that during long-term lung infections of CF
patients, activating mutations invade the population, driving SCV formation in vivo. The identification of mutational ‘‘scars’’
in the yfi genes of clinical isolates suggests that Yfi activity is both under positive and negative selection in vivo and that
continuous adaptation of the c-di-GMP network contributes to the in vivo fitness of P. aeruginosa during chronic lung
infections. These experiments uncover an important new principle of in vivo persistence, and identify the c-di-GMP network
as a valid target for novel anti-infectives directed against chronic infections.
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Introduction
Pseudomonas aeruginosa is an opportunistic gram-negative patho-
gen that predominates in late stage cystic fibrosis (CF) lung
infections [1]. Once established in the CF lung, P. aeruginosa is
impossible to entirely eradicate, with repeated relapses of infection
and the accompanying aggravation leading to progressive tissue
degradation and eventually to death. Over the course of long-term
chronic CF lung infections, P. aeruginosa undergoes phenotypic and
genetic adaptation to the lung environment, resulting in both a
progressive transition towards a persistent, low virulence state and
a related diversification into a number of distinctive phenotypes
[2,3]. These include mucoid cells, which overproduce alginate and
form distinctive slimy colonies [4], and small colony variants
(SCVs), slow-growing isolates that show strong attachment to
surfaces, auto-aggregation, enhanced exopolysaccharide produc-
tion and biofilm formation [5,6]. The appearance of SCVs
correlates with a prolonged persistence of infection, poor lung
function and increased antibiotic and serum resistance. Fatal
systemic infections after lung transplantation and increased serum
resistance have been associated with the recovery of SCVs of
Burkholderia species [7,8,9]. P. aeruginosa SCVs also emerge in other
situations that favor chronic infections including mechanically
ventilated patients or patients suffering from chronic obstructive
pulmonary disease [8,10]. These studies suggest that persistent
forms of P. aeruginosa represent genetic adaptations to the hostile
milieu in the patient, with characteristics including resistance to
phagocytosis [11], antimicrobial resistance due to slow growth or
increased persister cell populations [7,12], and reduced virulence
[13] potentially contributing to selection. Consistent with this, our
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recent work [11] demonstrated a causal link between P. aeruginosa
SCVs and persistence of infection in mice, supporting the
hypothesis that under certain infection conditions the SCV
phenotype confers a fitness advantage, and thus makes an
important contribution to the pathogenesis of P. aeruginosa lung
infections.
In recent years a strong link has emerged between enhanced
levels of the second messenger cyclic di-GMP (c-di-GMP)
[11,14,15,16] and the SCV phenotype, via overproduction of
exopolysaccharides [5,16] or fimbrial adhesins [14,17]. C-di-GMP
is a ubiquitous and widespread signaling molecule that has been
shown to influence a diverse range of cellular processes involved in
the transition from a motile, single-cell lifestyle to sessile, surface
attached consortia called biofilms [18,19]. In P. aeruginosa c-di-
GMP regulates multiple cellular processes, including exopolysac-
charide production [20,21,22], exposure of fimbrial and protein-
aceous adhesins [23,24], rhamnolipid biosynthesis [25], side-
rophore production [11], and virulence and cytotoxicity systems
[26,27,28], as well as assembly and function of pili [29,30,31] and
flagella [32]. Since many of these cellular processes are subject to
phenotypic adaptation during chronic P. aeruginosa lung infections,
enzymes involved in c-di-GMP metabolism have emerged as
possible targets of the underlying genotypic variation [2,11,14].
YfiBNR [11,33] (also called AwsXRO [34,35,36], TpbB [37]) is
a tripartite signaling system that modulates intracellular c-di-GMP
levels in response to signals received in the periplasm [11]. The
effector of the Yfi system, YfiN, is a membrane integral
diguanylate cyclase consisting of a periplasmic PAS domain and
cytoplasmic HAMP and catalytic GGDEF domains (Figure 1A).
YfiN activity is repressed by the soluble periplasmic protein YfiR
and stimulated by the outer membrane lipoprotein YfiB [11]. C-
di-GMP produced by YfiN stimulates the production of the Pel
and Psl exopolysaccharides, thereby promoting surface attachment
in wild-type P. aeruginosa and generating an SCV phenotype when
YfiN is activated or YfiR repression is released [11]. Homologs of
the YfiBNR system are widespread, and have been shown to
function similarly in Escherichia coli, Klebsiella pneumonia and
Pseudomonas fluorescens SBW25, where they affect biofilm formation
through cellulose production [33,34] or Type 3 fimbriae
expression [38].
While the epistasis and mode of output of YfiBNR have been
established [11], the mechanistic principles of YfiBNR control
remain to be determined. Central unanswered questions include
the nature of activating signals and the mechanism of YfiN
activation. The periplasmic protein YfiR plays a key role in the
signal transduction process as it bridges between the YfiN
diguanylate cyclase in the inner membrane and the presumable
YfiB sensor in the outer membrane. However, no structural or
mechanistic information is available for any members of the YfiR
family. In particular, it is unclear how YfiR interacts with the
periplasmic PAS domain of YfiN. PAS are versatile domains that
activate downstream signaling processes through a range of
different mechanisms [39,40,41,42] including ligand binding
[41], light/oxygen-driven modification of bound flavin or heme
groups [43,44], homodimerization [45] and, in eukaryotes,
Figure 1. Interactions between the YfiBNR proteins. A) A model
of yfiBNR interaction. YfiN is a membrane-localized DGC controlled by
YfiR. YfiB, the outer-membrane bound Pal-like protein, activates YfiN by
sequestering YfiR. B) Co-immunoprecipitation of YfiN with flag-tagged
YfiN and YfiR. Immunoblot of boiled M2 resin samples with anti-YfiN
antiserum shows YfiN (lower band) co-precipitating with YfiN-flag
(upper band) or YfiR-flag. C) Membrane localization of YfiB and YfiR.
Immunoblots of fractionated membrane samples with anti-YfiB (upper
panel) and M2 antisera (lower 2 panels). The left two panels show
membrane fractions for PA01 yfiR-M2, the right panel for DyfiBN yfiR-M2.
IM1/2: inner membrane fractions, OM1/2: outer membrane fractions.
doi:10.1371/journal.ppat.1002760.g001
Author Summary
Here we investigate the molecular function of the
important cyclic-di-GMP signaling system YfiBNR in the
opportunistic pathogen Pseudomonas aeruginosa and
demonstrate its importance for the evolution of persistent
small colony variant (SCV) morphotypes in chronic cystic
fibrosis (CF) lung infections. Previously we showed that
YfiN is a membrane bound diguanylate cyclase, whose
activity is controlled by the soluble periplasmic repressor
YfiR and the outer-membrane peptidoglycan binding
protein YfiB. In this study we use a combination of genetic
and biochemical analyses to investigate the mechanistic
principles of YfiN regulation. By examining a series of
activating mutations throughout the yfi operon, we show
that YfiBNR functions via tightly controlled competition
between allosteric binding sites on the three Yfi proteins; a
novel regulatory mechanism that is apparently widespread
among periplasmic signaling systems in bacteria. We then
show that during long-term CF lung infections, Yfi
activating mutations invade the population, driving SCV
formation in vivo. The identification of mutational ‘‘scars’’
in the yfi genes of clinical isolates further suggests that Yfi
activity is both under positive and negative selection in
vivo, with Yfi-mediated SCVs acting as an environmental
pool for the generation of new smooth morphotypes.
YfiBNR Signal Transduction Mechanism
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heterodimerization [46,47]. However, given the apparent ubiquity
of PAS domains in bacterial signal transduction processes [48]
additional activation mechanisms likely exist. Finally, the role and
mode of action of YfiB have remained elusive. Epistasis
experiments place YfiB upstream of YfiR, and suggest that YfiB
activates YfiN by relieving YfiR-mediated repression [11]. YfiB is
a structural homolog of Pal, a peptidoglycan binding protein and
component of the Tol-Pal pathway required to maintain cell
envelope integrity and function [49,50,51,52], although it is
unclear whether or not the two proteins are also functional
analogs.
In this study we map several adaptive mutations in P. aeruginosa
SCV isolates from CF patients to the c-di-GMP regulatory yfiBNR
locus. Moreover, through the elucidation of the signal transduction
mechanisms of the YfiBNR system we present a molecular rationale
explaining how this system contributes to the evolution of distinct P.
aeruginosa phenotypes and how the consecutive selection of gain- and
loss-of-function yfiBNR mutations might contribute to P. aeruginosa
adaptation in CF lungs. Firstly, a combination of genetic and
biochemical analysis was used to produce a detailed molecular map
of YfiBNR function. Through the isolation and characterization of
‘‘locked-on’’ and compensatory mutant alleles of all three compo-
nents of the system, we provide evidence that YfiR inhibits YfiN
allosterically, through a hydrophobic interaction between the C-
terminus of YfiR and a conserved region of the periplasmic PAS
domain of YfiN. Subsequent in silico analysis suggests that this YfiR-
YfiN interaction represents a novel and widespread periplasmic
signaling module, controlling diverse cytoplasmic outputs in a
variety of species. YfiN repression is released through an YfiB-
dependent sequestration of YfiR to the outer membrane fraction.
The resulting structural rearrangements in YfiN are then propa-
gated from the external PAS domain through the transmembrane
helices and HAMP domain to activate the C-terminal catalytic
GGDEF-domains. Our results suggest that the YfiB lipoprotein that
spans the outer membrane and the peptidoglycan acts as a sensor of
the YfiBNR system, and may be involved in transducing envelope
stress into a rapid increase of c-di-GMP inside the cell and
consequent biofilm formation through activation of the Pel and Psl
exopolysaccharide systems.
In parallel, screening strategies with two libraries of clinical P.
aeruginosa strains isolated from CF patients identified a number of
SCVs with causal mutations throughout the yfiBNR locus.
Activating substitutions were found in YfiN and a loss-of-function
mutation was isolated in YfiR. In addition, several SCVs harbored
mutations in the predicted yfiBNR promoter region. The
observation that most of these mutations match the ‘‘locked-on’’
mutations that we isolated by in vitro genetics strongly argues that
P. aeruginosa SCVs arise in patients’ lungs through genetic
alterations that activate the Yfi signaling system. Furthermore,
the subsequent identification of clinical isolates containing both yfi
activating mutations and loss-of-function mutations in yfiN suggests
that the environment in the lung alternates over time between
states that favor and disfavor the formation and fitness of SCVs.
Thus, Yfi-mediated SCVs are under positive and negative
selection in the dynamic environment of the CF lung thereby
enabling P. aeruginosa to switch between slow growing and
persistent SCVs and fast growing smooth morphotypes.
Results
The periplasmic regulator YfiR shuttles between inner
and outer membrane
YfiN has previously been shown to function as a membrane
bound diguanylate cyclase (DGC) whose activity is repressed by
the soluble periplasmic protein YfiR [11,35]. However, the
mechanism of YfiR repression is currently unknown. The simplest
potential repression mechanism is allosteric inhibition via direct
binding of YfiR to the periplasmic PAS-like domain of YfiN. To
test whether YfiR interacts with YfiN, co-immunoprecipitation
experiments were carried out using an YfiR variant with a C-
terminal flag tag. Wild-type YfiN was successfully pulled down by
YfiR-flag (Figure 1B), indicating that these proteins interact and
that YfiR might function by allosterically inhibiting YfiN activity.
Furthermore, YfiN-flag was also shown to interact with YfiN wild
type (Figure 1B), indicating that YfiN dimerizes in vivo, in common
with other diguanylate cyclases [53].
YfiB is predicted to be an outer membrane lipoprotein on the
basis of primary structure analysis and the fact that the protein is
found exclusively in the insoluble fraction of lysed PA01 [11]. This
was confirmed by membrane fractionation experiments that
located YfiB exclusively in the outer membrane fractions
(Figure 1C). Although co-immunoprecipitation experiments failed
to show direct interaction between YfiB and YfiR (data not
shown), YfiR-flag localization to the outer membrane fraction is
strictly YfiB-dependent. In the absent of YfiB, YfiR-flag is stable
(Figure S1B), but no longer associates with the membrane
(Figure 1C, S1A).
Isolation of constitutive mutants delineates the mode of
YfiN diguanylate cyclase activation
If YfiR represses YfiN activity through direct binding to its
periplasmic PAS domain, it should be possible to isolate
constitutively active YfiN variants that fail to bind YfiR. The
positions of these activating residue substitutions would conse-
quently provide insights into the mechanism of YfiN function and
the binding interface of YfiN and YfiR. Previously, similar
experiments have been successfully used to probe the structure-
function relationship of the P. fluorescens DGC WspR [54,55]. To
identify YfiR-insensitive YfiN alleles, a screening system was
designed in which yfiN and yfiR-flag are expressed from two
separate plasmids in a DyfiNR background (see Materials and
Methods). A pool of yfiN variants was produced by XL-1 red
mutagenesis of the yfiN plasmid and screened for mutants that
induced an SCV phenotype in the DyfiNR tester strain containing
a plasmid-borne copy of yfiR. Sequencing identified the locations
of twenty independent, activating yfiN mutations. Two residues
were identified in the first transmembrane helix, ten were located
towards the N-terminal end of the periplasmic PAS domain, four
were found in the second transmembrane helix, and four towards
the C-terminal end of the HAMP domain (Figure 2A). No
mutations were found in the GGDEF domain. Since most of these
mutations were isolated several times independently, we assume
that the screen was approaching saturation (Table 1).
Co-immunoprecipitation experiments showed that most of the
activated YfiN alleles no longer bind to YfiR-flag (Figure 2B). In
five cases (V68A, A171V, G173S, D204N, and A226T), residual
YfiN-YfiR binding was still observed. In accordance with this,
these five mutants produced the mildest phenotypes, with
relatively low levels of surface attachment (Figure 2C) and partial
SCV colony morphologies (Figure S2A). Expression of these five
yfiN alleles in a DyfiNR strain produced a distinctive SCV
phenotype (data not shown), indicating that the weaker SCV
morphology seen with these alleles is likely due to partial inhibition
by YfiR, rather than loss of YfiN function. The observation that
activating mutations in YfiN abolished YfiR binding indepen-
dently of their position within the protein (Figure 2B), suggested
that the protein switches between discrete active and inactive
YfiBNR Signal Transduction Mechanism
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states, and that the YfiR binding site is obscured in the active
conformation.
A clearer suggestion of how YfiN functions was obtained when
the positions of the YfiR-insensitive mutations were marked on
homology models of the PAS and HAMP domains of YfiN.
Activating mutations in the PAS domain appear to cluster into two
regions of the 3-D structure modelled on the periplasmic domain
of the sensor kinase CitA [41]. Assuming a similar dimerization
mechanism for YfiN, the first group of substitutions would cluster
at the interface between the two protein monomers (Figure 2D, 2E
pale blue), where they might help to stabilize the active YfiN
conformation. The remaining substitutions cluster on the domain
surface most distal from the inner membrane. Three of these
residues (Ala66, Ala67 and Val68) coordinate the position of the
fourth (Phe70), which protrudes into the periplasmic space. These
residues are predicted to form an exposed hydrophobic patch on
the surface of the PAS domain, which we propose as a possible
YfiR binding site (Figure 2E; dark blue). The four mutations in the
HAMP domain lie close to one another and distal to the inner
membrane (Figure 2F). Three mutations (positions 226, 228 and
232) are adjacent to residues required for helical bundle formation
[56]. Specific substitutions at these positions may act to stabilise an
active HAMP conformation relative to the inactive structure
[56,57]. In support of this, a substitution at the equivalent position
to Glu232 in NarX renders the protein constitutively active [58].
The D204N mutation occupies an equivalent position in the
helical linker region to the structurally important Leu237 residue
of the E. coli serine-specific chemoreceptor Tsr. Mutations in this
position have been shown to stabilise the activated form of Tsr
[59,60], suggesting a similar mechanism for the YfiN mutation.
Taken together, these results demonstrate that YfiN activation is
crucially dependent on a number of key residues involved in intra-
molecule signal transduction and on interfering with YfiR binding.
We propose that the release of YfiR results in a conformational
shift of the entire YfiN protein towards an active state, in which
binding of the repressor is disfavored.
Compensatory mutations cluster in defined regions of
the YfiR protein
To probe the YfiN-YfiR interaction in more detail, we
undertook a screen for compensatory yfiR alleles, i.e. alleles that
would restore wild-type (WT) colony morphology in the presence
of some of the activated YfiN variants introduced above. Following
PCR mutagenesis of yfiR, twenty-one alleles were isolated across
eight yfiN mutant backgrounds (Table 2). Several yfiR alleles were
independently isolated in several constitutive yfiN backgrounds,
resulting in a total of fourteen unique, compensatory yfiR alleles,
most of which cluster in the secretion signal sequence or in the C-
terminal region of the protein (Table 2, Figure 3B). As the signal
peptide is cleaved following export of YfiR into the periplasm,
mutations in this region are not predicted to affect the final protein
structure. Rather, these mutations might boost YfiR levels in the
periplasm through increased translation or export of the protein.
This was confirmed by immunoblot analysis demonstrating that
signal peptide mutants indeed produced higher overall levels of
YfiR than wild-type (Figure 3).
Compensatory mutations in the C-terminus of YfiR were
isolated in three distinct yfiN mutant backgrounds, all of which
produced mild SCV phenotypes and showed residual binding of
YfiR (Table 1, Figure 2). This suggests that mutations in this
region of YfiR enhance binding to YfiN, but cannot compensate
for a total loss of protein-protein interaction. In a cross-
complementation experiment, all four C-terminal YfiR mutants
(F151L, E163G, I169V and Q187R) were able to suppress the
Figure 2. Activating mutations in YfiN. A) Locations of activating
mutations in YfiN. Arrows indicate the positions of activating mutations
throughout the structure of YfiN. TM: transmembrane helix. The cartoon
is drawn to scale. B) Co-immunoprecipitation of active YfiN alleles with
flag-tagged YfiR. Immunoblot of boiled M2 resin samples with anti-YfiN
antiserum. N-WT shows the DyfiNR screening strain with both yfiN (WT)
and yfiR-flag plasmids present. Ctrl. shows DyfiNR with pGm-yfiprom-N
only. The point mutation present in YfiN is indicated for the remaining
lanes, which show YfiN immunoprecipitated from DyfiNR strains
containing both yfiR-flag and the mutated yfiN plasmids. C) Attachment
of the active YfiN alleles is shown relative to DyfiNR pGm-yfiprom-N,
pMR-yfiR-flag (p-yfiN p-yfiR). Controls containing the yfiN or yfiR-flag
plasmid only are also shown. The point mutation present in YfiN is
indicated for each bar. Light grey bars indicate mutants whose activity
was compensated for by mutations at the C-terminus of YfiR. Mutants
with mid grey bars were compensated for by mutations in the signal
sequence, or by uncharacterized mutations, while those with dark grey
bars were not compensated for during YfiR mutagenesis. The domain
locations of mutants are indicated with TM, PAS etc. D) Cartoon
showing the locations of activating substitutions (blue) on a homology
model of the YfiN PAS domain (residues 44–154). The PAS model is
based on the CitA periplasmic domain (see Materials and methods). E)
Surface representation of the YfiN PAS model. The locations of
activating mutants on the proposed homodimer interface are shown
in light blue, those at the possible YfiR binding site are shown in dark
blue. F) The locations of activating substitutions (blue) on a homology
model of the YfiN HAMP domain (residues 183–236). N and C termini
are marked in D) and F). The HAMP model is based on the Aer2 HAMP
structure (see Materials and methods).
doi:10.1371/journal.ppat.1002760.g002
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Table 1. YfiR-insensitive YfiN alleles.
Location in YfiN Residue change Notes
First TM helix A33T
V40A
PAS, dimerization interface P51S
R58C
S59P Equivalent mutation activates AwsX [35].
Y62H
A66V
A67P
A67V
V68A
F70L
E87K Mutation present in Clin110.
Second TM helix G162S
A171V
G173S
G173D Mutation present in SCV20265.
HAMP D204N Mutation at the equivalent position activates Tsr [59].
A226T
L228F
E232D Mutation at the equivalent position activates NarX [58].
PAS refers to the periplasmic PAS domain; HAMP refers to the HAMP domain.
doi:10.1371/journal.ppat.1002760.t001
Table 2. Compensatory YfiR alleles.
YfiN allele No. YfiR residue change(*) Location in YfiR
Y62H 12 V21I Signal peptide
13 D11N Signal peptide
A66V 1 S3L, D11Y, T76N Signal peptide
A67P 10 V21I, Q187R Signal peptide/proposed YfiN binding site
V68A - R93S, I169V proposed YfiN binding site
- E163G proposed YfiN binding site
- Q187R proposed YfiN binding site
3 G29S, V112A undefined
4 S3T, D36E Signal peptide
5 V21I Signal peptide
6 L7S Signal peptide
G162S - Q125L undefined
D204N - K63E conserved region of YfiR
- I169V proposed YfiN binding site
11 V21I Signal peptide
A226T - E163G proposed YfiN binding site
7 L1M, Q10P, M86T, D102G, V135A Signal peptide/improved start codon
8 V21I Signal peptide
- F151L proposed YfiN binding site
9 Q8H, I169V proposed YfiN binding site
L228F 2 Q8H, R60H conserved region of YfiR
(*)proposed activating mutations are highlighted in bold.
doi:10.1371/journal.ppat.1002760.t002
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SCV phenotype of all three weak YfiN mutants (Figure S2B),
indicating that the enhanced effectiveness of these mutants was the
result of an overall increase in YfiR binding affinity, rather than
through complementation of specific YfiN mutations. When
plotted onto a homology model of YfiR, the four C-terminal
mutations surround a hydrophobic region on the surface of the
model (Figure 3B) that presents a possible candidate for the YfiN
binding surface. These residues are highly conserved among YfiR
homologs, especially the central Phe residue at position 162.
Likewise, despite little overall conservation of the YfiN PAS
domain, the predicted YfiR binding site on its surface (‘AAVVF’
motif) is highly conserved, but absent in the PAS domain of CitA
[41,61] (see below).
A plausible model for YfiN-YfiR interaction arises from these
observations, in which the exposed phenylalanine on the surface of
YfiN is hidden from the aqueous environment by hydrophobic
interaction with the C-terminus of YfiR. Together, these data
demonstrate that activating yfiN alleles can be overcome by
compensatory mutations in yfiR, again lending support for a direct
repression of YfiN by the periplasmic protein YfiR.
Genetic dissection of the YfiB outer membrane sensor
YfiB is predicted to be an outer-membrane lipoprotein with a
PAL-like peptidoglycan (PG) binding domain. Overproduction of
YfiB leads to YfiN-dependent SCV formation [11]. How this effect
is exerted on YfiN is not clear and no detailed model for YfiB
function in P. aeruginosa exists. To investigate the function of YfiB,
a screen was conducted for activating mutants that induced an
SCV phenotype in PA01 without overproduction of the protein. A
total of 20 yfiB alleles were isolated, each containing one or more
amino acid substitutions. All activating yfiB alleles caused
increased surface attachment and biofilm formation (Figure 4A).
Strikingly, while mutations were distributed throughout the
sequence of yfiB, at least one substitution was found between
residues 35 and 55 in all cases. These affected a total of seven
positions, five of which were also isolated as single activating
substitutions (Figure 4A). Alleles with single mutations in the YfiB
N-terminus generally had strong effects that were weakened by the
presence of secondary mutations (for example, YfiB L43P
produces higher attachment than L43P alleles containing addi-
tional mutations). Together this argued that the majority of
mutations leading to YfiBNR activation cluster in this region of the
YfiB protein. Some of these variants had very strong activating
effects despite showing severely reduced stability (Figure 4A).
Three further, similar substitutions (I40F, V42M, and E45G) were
found in conjunction with other singly isolated activating
mutations. While neither the V42M nor the E45G substitutions
contributed positively to YfiB activity, the YfiB-I40F-F48L allele
produced a far stronger phenotype than F48L alone, suggesting
that the I40F mutation also contributes to YfiB activation
(Figure 4A). When the locations of the activating mutations were
plotted onto a 3-D homology model of YfiB, they clustered around
the first helix of the PAL domain (Figure 4B). Interestingly,
activating residues in YfiB surround a predicted surface-exposed
hydrophobic region, similar to that seen in the model of YfiR
(Figure 3C). This hydrophobic patch is highly conserved in YfiB
homologs, but absent in the YfiB structural homolog OprL
[61,62]. Most notably, W55, predicted to form the core of the
hydrophobic binding site, is very highly conserved, only replaced
in a small minority of cases with phenylalanine (note that the YfiB
W55L mutation forms a weak SCV in PA01).
To determine whether binding to PG is important for YfiB
function, mutants were constructed with two critical peptidogly-
can-binding residues [63] replaced with alanine. Expression of the
resulting gene, yfiB-D102A-G105A (PG-) did not induce an SCV
colony morphology and had no effect on attachment, despite
producing wild type-like levels of protein (Figure 4D, E). To assess
the role of the YfiB OM lipid anchor (LA), the YfiB signal peptide
was replaced with that from YfiR, which lacks the Cys lipid
acceptor residue. The resulting mutant (LA-) slightly increased
attachment upon induction in an YfiN-dependent manner
(Figure 4D). This residual activity was dependent on peptidoglycan
binding, as a PG-/LA- mutant was fully inactive (Figure 4D).
These data suggest that peptidoglycan binding and, to a lesser
extent, membrane anchoring are required for YfiB activity. When
the mutations disrupting PG binding were combined with
activating mutations in yfiB (F48S or L43P; see above), very low
YfiB protein levels were detected, possibly as a result of reduced
protein stability (Figure 4D). Importantly, the resulting alleles still
led to increased attachment and generated an SCV phenotype
(Figure 4D, E). This suggested that the activating mutations are
dominant over the loss of peptidoglycan binding, and that they are
able to fix YfiB in its active conformation independent of PG
binding.
YfiB sequesters YfiR at the outer membrane (Figure 1). To
examine the relationship between this activity and YfiB function,
membrane fractionation was carried out for strains expressing PG-
and hyperactive (F48S) YfiB variants alongside an yfiR-flag allele.
While wild-type YfiB and the constitutive mutant F48S were able
to sequester YfiR to the outer membrane fraction, no localization
was seen for the PG binding mutant of YfiB (Figure 4C). Together,
these data suggest that YfiB is able to release YfiN repression by
sequestering YfiR at the outer membrane and that this activity
requires both YfiB peptidoglycan binding and anchoring in the
outer membrane. Since we were unable to co-immunoprecipitate
YfiB and YfiR, it is unclear if YfiB sequesters YfiR through direct
Figure 3. Compensatory YfiR alleles. A) Immunoblots with M2
antiserum, showing levels of compensatory YfiR-flag variants in whole
cell lysates. pyfiR: DyfiNR pMR-yfiR-flag, DyfiNR: strain without vector,
pyfiN/pyfiR: DyfiNR pGm-yfiprom-N, pMR-yfiR-flag, lanes 1–13: DyfiNR
pGm-yfiprom-N with compensatory pMR-yfiR-flag plasmids, proposed
activating mutations are highlighted in bold. Mutants in lane 1, 4–8, 10–
13 harbor mutations in the signal peptide that enhance expression, see
also Table 2. B) Cartoon showing the locations of activating
substitutions (green) on a homology model of YfiR (comprising residues
68–190). N and C termini are marked. The YfiR model is based on
multiple structures (see Materials and methods). C) Surface represen-
tation of the YfiR model. The locations of activating mutants are shown
in green, hydrophobic residues forming the possible YfiN binding
surface are shown in dark blue.
doi:10.1371/journal.ppat.1002760.g003
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protein-protein contact or if additional component(s) mediate this
interaction.
The finding that both lipid anchor and peptidoglycan binding
are required for full activity of YfiB, together with the mapping of
gain-of-function mutations close to the YfiB N-terminus, prompted
us to examine the role of the N-terminal linker region in YfiB
mediated signaling. The need for YfiB anchoring in cell wall and
outer membrane suggests that YfiR sequestration might respond to
the distance spanned by the protein. To test this, we modulated
the length of the 13-amino acid long linker connecting the lipid
acceptor cysteine with the PAL domain (Figure 5A). While
extending the linker by 9 amino acids produced only a modest
attachment effect upon induction (Figure 5C), shortening the
linker by 5 amino acids produced a strong constitutive phenotype
with respect to YfiR sequestration to the outer membrane
(Figure 5B), surface attachment (Figure 5C), and SCV morphology
(Figure 5D). This suggests that the linker region plays an important
role in YfiB-mediated signaling and that YfiR sequestration might
critically depend on the ‘wingspread’ of the YfiB connector
between the two outermost layers of the cell.
YfiBNR as a potential periplasmic stress sensor system
The above experiments, together with the observation that the
YfiB homolog Pal is involved in cell envelope homeostasis and
function [64] argued that YfiB might induce an up-regulation of c-
di-GMP levels in response to cell envelope stress. Consistent with
this, the YfiBNR system plays a role in the cellular response to
elevated salt concentrations (high osmolarity) and exposure to
outer-membrane disturbing detergents like SDS (Figure S3).
However, while such a mechanism is consistent with our
experiments suggesting that YfiB envelope anchoring is important
for its regulatory role, attempts to link YfiB to distinct forms of
envelope stress have so far remained unsuccessful.
In silico analysis of available bacterial genome sequences
revealed that the Yfi signaling family is widespread in gram-
negative bacteria and that several of its members lacked the
Figure 4. Mutational analysis of YfiB. A) The effect of activating yfiB mutants, expressed from pME6032 in DyfiBNR Tn7::yfiNR, on attachment is
shown relative to PA01 (PA01 ctrl.). ‘YfiB WT’ indicates pME6032-yfiB. The point mutants in YfiB are indicated for the remaining lanes. Those mutations
thought to contribute to YfiB activation are marked in bold. The immunoblot shows the levels of YfiB protein present in each strain. B) Left: Cartoon
showing the locations of activating substitutions (red) on a homology model of YfiB (comprising residues 27–168). The YfiB model is based on the
Omp/Pal structure (see Materials and methods for details). The N terminus and peptidoglycan binding site are marked. Right: Surface representation
of the YfiB model. The locations of activating mutants are shown in red, hydrophobic residues forming the possible YfiR binding surface are shown in
dark blue. C) Co-localization of YfiB and YfiR at the outer membrane. Immunoblots of fractionated soluble and membrane samples with anti-YfiB and
M2 antisera as shown. ‘YfiB WT’ indicates DyfiBNR Tn7::yfiR-flag containing pME6032-yfiB. ‘PG-’ indicates the same background strain containing pME-
yfiB-PG- (YfiB containing the D102A and G105A substitutions), while ‘F48S’ contains the hyperactive yfiB F48S plasmid. D) The effect of different yfiB
mutants, expressed from pME6032 in DyfiBNR Tn7::yfiNR, on attachment is shown relative to pME6032 only (ctrl.). ‘PG-’ mutants 6 F48S or L43P
mutations as indicated. In ‘LA-’ mutants, the lipid anchor is missing, the signal peptide has been replaced with that from YfiR. ‘DBNR LA-’ indicates the
yfiB LA- mutant in the DyfiBNR strain background. The immunoblot shows the levels of YfiB protein present in each strain. E) Colony morphologies on
LB Congo-red agar upon over-expression of yfiB mutants.
doi:10.1371/journal.ppat.1002760.g004
Figure 5. Effect of YfiB linker mutants. A) Sequence of the N-terminal YfiB ‘linker’, between the outer membrane (lipid anchor on the highlighted
cysteine) and the Pal-like domain. The first activating mutant position (Figure 4) is shown in red. ‘short-linker’ indicates a deletion of 5 amino acids,
leaving the lipobox intact. ‘long-linker’ indicates an insertion/duplication of 9 amino acids (dashed line). B) Co-localization of YfiB and YfiR at the outer
membrane. Immunoblots of fractionated soluble and membrane samples with anti-YfiB and M2 antisera as shown. ‘YfiB WT’ indicates DyfiBNR
Tn7::yfiNR containing pME6032-yfiB. ‘short’/‘long’ indicate the strains containing pME6032-yfiB linker mutants. C) The effect of different yfiB mutants,
expressed from pME6032 in DyfiBNR Tn7::yfiNR, on attachment is shown relative to pME6032 only (ctrl.). The immunoblot shows the levels of YfiB
protein present in each strain. D) Colony morphologies on LB Congo-red agar upon over-expression of yfiB mutants.
doi:10.1371/journal.ppat.1002760.g005
YfiBNR Signal Transduction Mechanism
PLoS Pathogens | www.plospathogens.org 8 June 2012 | Volume 8 | Issue 6 | e1002760
respective YfiB component (see below). This argued for an
additional level of signal input within this regulatory network. In a
previous screen for mutants leading to an SCV phenotype [11], we
identified transposon insertions in PA5489 that codes for the
periplasmic thiol:disulfide interchange protein DsbA. This protein
catalyzes cysteine crosslinking, and is responsible for the correct
folding of periplasmic proteins [65]. Given that YfiR contains four
highly conserved cysteines, we hypothesised that disruption of
DsbA may result in YfiR misfolding and consequent release of
YfiN repression (YfiN contains no periplasmic cysteines). To test if
the dsbA SCV phenotype was dependent on the Yfi system, dsbA
was deleted in PA01 wild type and in different yfi mutant strains.
Deletion of dsbA produced a strong SCV phenotype in PA01 and
in the yfiB mutant, but not in the DyfiBNR strain (Figure 6A).
Other phenotypes associated with dsbA deletion such as a
reduction in secreted protease levels were unaffected in the
DyfiBNR background (data not shown). Also, disruption of the
wspR gene encoding another major P. aeruginosa diguanylate
cyclase [15], did not abrogate the SCV phenotype of the DdsbA
background (Figure 6A). Consistent with a lower YfiR stability
resulting from protein misfolding, YfiR levels, but not YfiN levels,
were markedly reduced in the DdsbA background as compared to
wild-type PA01 (Figure 6B). Finally, the DdsbA SCV phenotype
could be abolished by over-expression of yfiR-flag in trans
(Figure 6A,B). Altogether, this suggested that in the absence of
DsbA, misfolding of YfiR leads to specific activation of the YfiN
diguanylate cyclase.
The observation that YfiR activity requires DsbA suggested that
reducing conditions in the periplasm might block YfiR and lead to
YfiN activation. To test this, growth and surface attachment were
scored for various PA01 mutants with increasing concentrations of
the reducing agent DTT. As shown in Figure 6C, deleting yfiBNR
markedly increased the sensitivity of PA01 to reducing conditions.
While the yfi+ strain showed attachment up to 20 mM DTT, the
yfi mutant showed no attachment above 2.5 mM DTT. Impor-
tantly, deletion of yfiB alone had no appreciable effect on PA01
growth or attachment in DTT, strongly suggesting that the
activation of YfiN under reducing conditions is a consequence of
YfiR misfolding rather than signaling through YfiB (Figure 6C).
Together, these data suggest that YfiR constitutes an YfiB-
independent sensing device that is able to activate the YfiN
diguanylate cyclase in response to the redox status of the
periplasm.
The YfiBNR system is under positive and negative
selection in CF lungs
‘‘In vitro’’ mutagenesis of the yfiBNR operon has revealed
several routes to Yfi-mediated SCV formation. Disruption of yfiR
induces a strong SCV phenotype [11], and activating mutations
can arise in yfiN or yfiB (Figure 2, 4). To determine whether
Figure 6. Reducing effects on yfiBNR activity. A) Colony morphologies of yfiBNR/dsbA single and double mutants on LB Congo-red agar.
Indication of the following abbreviations: DBNR – DyfiBNR, DB – DyfiBNR Tn7::yfiNR, DR – DyfiR, pR-flag – pMR-yfiR-flag, pdsbA – pME6032ara-dsbA,
pME – pME6032ara. B) Immunoblots of PA01 and DdsbA with M2 and anti-YfiN antisera, showing levels of YfiR-flag and YfiN in whole cell lysates. C)
The effect of increasing concentrations of DTT on attachment (bars), of the DBNR and DB mutants is shown relative to wild-type PA01. Curves
represent relative optical density with standard errors.
doi:10.1371/journal.ppat.1002760.g006
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mutations in the yfi genes were responsible for the SCV
phenotypes of clinical P. aeruginosa isolates from CF patients, we
sequenced the yfiBNR operon of clinically derived SCVs and
analyzed the contribution of candidate SNPs. Firstly, 45 clinical
SCV strains were pooled and their genomes sequenced (S.
Ha¨ussler and A. Do¨tsch, unpublished data). The yfiBNR operon
sequence of each pool (representing a consensus sequence drawn
from 15 individual SCV genome sequences) was compared with
that of PA01, the positions of SNPs were identified (Table S3), and
non-synonymous SNPs reproduced and introduced into the SCV
screening strains described above (for details see Materials and
Methods). From a total of 11 mutations identified, seven showed
no noticeable effect. However, several mutations were identified in
yfiN (G173D, D223N, L227M) or yfiR (C26R) that induced an
SCV morphology and greatly enhanced attachment in the
screening strain (Figure 2C, 7A, D). The amino acid residues
altered in YfiN either matched (G173) or were located in the
immediate vicinity of positions (D223, L227) identified by in vitro
mutagenesis (Figure 2). These data demonstrate that SCVs arise in
the airways of CF patients through the selection of clones carrying
mutations in yfi genes that lead to de-repression the Yfi pathway.
Next, we analyzed two clinical SCV strains in more detail. First,
the SCV morphology and strong surface attachment of strain
Clin110 were suppressed by overexpression of yfiR in trans
(Figure 7B, E). Sequence analysis revealed that Clin110 YfiN
contained the activating mutation E87K (Figure 2; Tables 1, S3).
Interestingly, a second isolate (Clin163) was recovered 18 months
later from the sputum of the same patient and identified as a
descendent of Clin110 by comparison of synonymous SNPs
throughout the yfiBNR operon. Clin163 displayed a smooth colony
morphology and low surface attachment (Figure 7B, E), in spite of
the fact that it contained the yfiN E87K mutation. Clin163
harbored an additional mutation (G329C) in the GGDEF active
site motif of the diguanylate cyclase domain. As such active site
mutations are known to destroy enzyme activity [54], this strongly
suggested that the recovery of smooth colony morphology in
Clin163 was due to YfiN inactivation (Figure 7B). In support of
this, the c-di-GMP level in Clin110 (15176280 pmol/mg protein)
was measured, and shown to be ,30 times higher than in PA01
(51.5620.7). The level in Clin163 in contrast, was much lower
(114641.6). Finally, expression of a phosphodiesterase in trans
markedly reduced Clin110 attachment (Figure S4). Second, we
Figure 7. Clinical YfiBNR mutants. A) Colony morphologies of DyfiNR pGm-yfiprom-N, pMR-yfiR-flag strains with the point mutants indicated
present in either YfiR or YfiN. ‘WT’: both plasmids contain wild-type yfiN/yfiR alleles. All colony morphologies are on LB Congo-red agar. B) Colony
morphologies of Clin110 and Clin163 strains. pR indicates that the strain contains pME-araC-yfiR, the asterisk indicates induction. C) Colony
morphologies of DyfiBNR strains complemented with the yfiBNR operon inserted into the att-Tn7 site. Mutations in the complementing copy of yfiN
are indicated in each case. ‘WT’: wild type yfiN. D) Attachment relative to DyfiNR pGm-yfiprom-N, pMR-yfiR-flag (pNpR) of clinical yfiN/yfiRmutants. ‘pR’
and ‘pN’ contain pMR-yfiR-flag or pGm-yfiprom-N only. E) Attachment of Clin110 6 pME-araC-yfiR and Clin163 relative to PA01.
doi:10.1371/journal.ppat.1002760.g007
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analyzed strain SCV20265, a clinical CF isolate whose SCV
morphology is abolished by transposon insertions in yfiN or yfiB
[14]. Sequence analysis of the yfiBNR operon from SCV20265
revealed two yfiN mutations; the activating mutation G173D
(Figure 2; Table 1) and an in-frame deletion of codons 255–257
within the GGDEF diguanylate cyclase domain (Table S3). To
determine their individual contributions, yfiBNR operons contain-
ing one or both yfiN mutations present were introduced into the
att::Tn7 site of a DyfiBNR strain. G173D alone induced a robust
SCV morphology in PA01, while the D255–257 deletion abolished
the SCV phenotype in combination with G173D (Figure 7C).
Furthermore, YfiN alleles containing only the D255–257 deletion
were completely inactive on the basis of attachment assays with
yfiN expression in trans (data not shown). While an SCV-inducing
mutation was found in SCV20265 YfiN, the final protein is
inactive. Clearly, additional SCV-inducing mutations must have
arisen to complement the loss of YfiN activity, the nature of which
is the subject of active investigation.
Together these data argue that the YfiBNR system is under
both positive and negative selection in P. aeruginosa colonizing the
lung of CF patients. Since SCV isolates have high reproductive
costs [11], it is possible that alternating selection for rapid growth
and persistence acts on the c-di-GMP network, thereby accumu-
lating gain- and loss-of-function alleles in key components like
YfiN.
Yfi defines a widespread and highly modular bacterial
signaling system
Homologs of the YfiB, YfiN, and YfiR proteins were
determined and plotted on a 16S rRNA-based phylogenetic tree
to represent the taxonomic spread of the system (Figure 8A), for
more details see Materials and Methods. 144 genomes were found
to contain complete or partial yfiBNR operons. Genera containing
complete, conserved yfiBNR operons (total 99) were found in the
alpha-, beta- and gamma-proteobacteria, with most examples
clustering in the gamma and beta classes. Two types of degenerate
yfi operons were also identified. Firstly, operons containing yfiN
and yfiB homologs in synteny, but no yfiR, were found in ten
predominantly gamma-proteobacterial genomes (Table S4). In
most cases, the transmembrane helices and GGDEF output
domain of YfiN, as well as the PAL domain of YfiB were
conserved. However, no homology was observed for the periplas-
mic domain of YfiN, and none of the proposed YfiR binding
residues were conserved (Figure 8C, D), indicating that these
systems function in a markedly different manner to P. aeruginosa
YfiBNR. Secondly, 35 genomes were identified containing all
three yfi homologs, but with only two of them in synteny (Table
S4). Closer examination suggested that the genes in synteny were
almost always yfiN and yfiR. The c-proteobacteria Salmonella and
Dickeya contain fully conserved yfiR and yfiN genes but lack yfiB.
Interestingly, with growing evolutionary distance from Pseudomonas
sp., the general divergence of the Yfi systems increased. Almost all
of these operons lacked an yfiB homolog, and in many cases the
GGDEF output domain of YfiN was replaced with GGDEF-EAL
pairs, histidine-phosphotransfer domains (HPT) or sensor histidine
kinases (Table S4). Variation was also seen at the level of signal
input. In Thauera sp. MZ1T a system was identified with two YfiR
homologs and a single YfiN with a hybrid sensor kinase output.
The genomic location of the yfiN-yfiR homologs was highly
variable, with some systems part of operons and others found
alone. Nonetheless, alignment of PA01 YfiR and YfiN with some
of the most divergent homologs revealed that the hydrophobic
residues identified above as important for function were conserved
throughout (Figure S5), suggesting that the basic concept of YfiR
regulation of YfiN remains unchanged even in these highly
divergent systems.
Altogether, these analyses suggest that the YfiR-YfiN[PAS] core
represents a widespread, highly modular and versatile signaling
system in bacteria that during evolution has integrated additional
signal inputs through the acquisition of YfiB and distinct activities
through the combination of different output domains.
Discussion
During long-term colonization of CF lungs, Pseudomonas
aeruginosa clones undergo specific genotypic adaptation to the host
environment. As a result, the genotypes of strains present in
advanced CF infections differ substantially from strains that
originally invade the respiratory tract of these patients [2]. During
adaptation to chronic behavior P. aeruginosa experiences a
widespread loss of virulence factors and concomitant ‘induction’
of persistence traits. However, little is known about the exact
nature of these traits or about the adaptive processes that lead to
their expression. In this study we investigate specific genetic
adaptations of the P. aeruginosa c-di-GMP signaling network and
their role in the establishment of chronic infections of CF lungs.
We demonstrate that during long-term lung infections, mutations
affecting the activity of key regulators of c-di-GMP production
invade the bacterial population in the lung, driving the formation
of persistent SCV morphotypes in vivo. Our studies concentrate on
the YfiBNR system, one of the previously identified clinically
relevant systems for c-di-GMP production in P. aeruginosa [11].
The finding that the YfiBNR proteins are subject to both positive
and negative selection allows us to make specific predictions
regarding the adaptive processes occurring during long-term
chronic infections of CF lungs, i.e. that the fitness landscape of the
lung is heterogeneous and dynamic, providing selective pressure
for both smooth and SCV phenotypes in different regions of the
lung, or periods during infection. The recognition of genetic
changes occurring in the patient was facilitated by a comprehen-
sive analysis of Yfi-mediated regulation in P. aeruginosa, emphasiz-
ing the importance of a thorough molecular and mechanistic
understanding of physiological and regulatory processes for the
analysis of adaptive behavior in vivo.
While the epistasis and physiological significance of the YfiBNR
system has been described previously [11,35], its mechanism of
action has remained largely unknown. We provide biochemical
and genetic evidence that the activity of membrane-integral
diguanylate cyclase YfiN is suppressed via interaction between its
extracellular PAS domain and the periplasmic repressor protein
YfiR. Release of repression, either by YfiR disruption or by YfiB-
mediated sequestration to the outer layer of the cell envelope leads
to a conformational shift in YfiN that propagates through the PAS
and transmembrane domains to switch the cytoplasmic HAMP
domain from an inactive to an active conformation. This
activating conformational change is subsequently transmitted to
the C-terminus, where DGC activity is likely determined by the
formation of a properly aligned GGDEF homodimer [53,66,67].
Thus, YfiN appears to function by switching between discrete
inactive and active functional states depending on the presence or
absence of bound YfiR. In this respect, YfiN is similar to a number
of other well-characterized transmembrane signaling proteins,
including histidine kinases and methyl-accepting chemotaxis
proteins [56] in which ligand binding provokes activating
conformational changes that propagate throughout the protein
structure.
Our analyses place YfiR at the center of the Yfi signaling
pathway with two potential interaction partners, YfiN and YfiB,
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Figure 8. In silico analysis of the YfiBNR system. A) Lineage tree illustrating the distribution of the yfiBNR genes along bacterial lineages.
Individual branches indicate separate genera. Genera marked in large, bold type contain species with complete yfiBNR operons. Those marked with
an asterisk (*) contain species with yfiB and yfiN only, conserved and in synteny. The remaining genera contain species with two yfi genes conserved
and in synteny (usually yfiN and yfiR) and a third yfi homolog elsewhere in the genome. Bacterial classes are indicated with coloured shading. Alpha,
Beta etc. refer to the respective proteobacterial class. B-D) Weblogo representations of YfiBNR residue conservation. The height of the letter in each
case indicates the degree of conservation at that position. Hydrophobic residues are coloured blue, hydrophilic residues red. Asterisks (*) indicate the
sites of activating mutations, while blue underlining indicates those residues suggested to contribute to a hydrophobic protein binding site. B) YfiB
residues 33–72. C) YfiN PAS-domain residues 48–87, YfiN HAMP-domain residues 198–237. D) YfiR residues 122–191.
doi:10.1371/journal.ppat.1002760.g008
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localized in the inner and outer membrane, respectively. Specific
partner selection of YfiR would then determine YfiN signaling
activity. YfiR appears to be unique, without functional homologs
in other signaling systems. Nonetheless, the combination of
mutagenesis, structural modeling and analysis of sequence
conservation applied in this study allowed us to propose that
YfiR may bind to YfiN via a hydrophobic binding site composed
of residues in the C-terminal region of the protein. Sequence
conservation indicates that hydrophobic amino acids (Val160,
Phe162, Leu183) on the surface of the modeled YfiR structure
may be especially important in this regard. Consistent with such a
mode of action, compensatory mutations in YfiR that are able to
suppress activated forms of YfiN are positioned in the immediate
vicinity of this hydrophobic patch. Likewise, our genetic studies
indicate that YfiR binds to a highly conserved stretch of five amino
acids (AAVVF) on the surface of the YfiN PAS domain. Even
conservative substitutions in this region abolish the YfiR binding
surface and lead to YfiN activation. It is possible that the valine
and alanine residues coordinate the central phenylalanine to
protrude into the periplasm thereby providing a hydrophobic
binding site for YfiR. To our knowledge, this is the first recorded
example of a prokaryotic PAS domain that signals via protein-
protein interaction. Structural studies are underway to clarify the
molecular details of this interaction.
YfiB spans the peptidoglycan and the outer membrane and
appears to function by sequestering YfiR away from the inner
membrane and YfiN. While direct YfiR-YfiB interaction could not
be demonstrated, YfiR localization to the outer membrane
fraction requires the presence and activity of YfiB. The location
of activating mutants in YfiB provided insight into the mechanism
of YfiB action, leading us to propose that activation may result
from the exposure of a patch of hydrophobic residues on the YfiB
surface, particularly the highly conserved tryptophan at position
55 (Figure 8). According to our model of YfiB structure and
topology, these hydrophobic residues form an YfiR binding site
immediately proximal to the insertion site of the protein into the
outer membrane. Since both peptidoglycan binding and outer
membrane anchoring are essential for YfiB function, the protein
might sense envelope integrity or the distance between the two
outermost layers of the cell, a mechanism that has also been
suggested for the outer membrane protein Pal [51]. Changes in the
relationship between the outer membrane and peptidoglycan
would expose or obscure the hydrophobic YfiR binding site,
controlling the amount of YfiR bound to YfiB and hence the level
of YfiN activation. Such a model is supported by the observation
that shortening of the linker between the Pal-like domain of YfiB
and its anchoring site in the outer membrane leads to YfiR
recruitment and activation of YfiN, while a longer linker retains
overall YfiB activity but does not lead to enhanced activation. A
corollary of this model is that the YfiR-YfiN interaction would
need to exist in a state of dynamic equilibrium, with some
unbound YfiR and YfiN present at all times. Rather than directly
challenging the YfiR-YfiN interaction, YfiB would act as a ‘sink’
for unbound YfiR, removing it from the periplasm and thus
shifting the equilibrium towards unbound, active YfiN.
The model for YfiBNR function proposed above implies a
biological role for the Yfi system in sensing physical stresses
affecting the outer membrane and/or the peptidoglycan, and
triggering c-di-GMP-dependent outputs as a response to that
stress. The nature of these output systems is the subject of ongoing
research, but is currently thought to focus on the control of
exopolysaccharide production at the transcriptional and post
transcriptional levels [11]. Our experiments failed to directly
demonstrate a role for YfiB in the response to envelope stress.
Although the Yfi system as a whole is required for full biofilm
induction at high osmolarity or in the presence of SDS, two
stressors that are known to affect the integrity of the cell envelope,
we could not demonstrate a specific role for YfiB in this process. In
addition to YfiB-mediated activation, YfiN can be activated by
YfiR disruption. This is most visible in a genetic yfiR mutant, but
may also occur when YfiR does not fold correctly due to
incorrect/incomplete cysteine crosslink formation. The four
cysteine residues in YfiR are strictly conserved amongst complete
YfiBNR systems, supporting their importance for YfiR function.
In response to external reducing agents P. aeruginosa stages a
biofilm response that fully depends on the presence of YfiN and
YfiR, but not YfiB, and which greatly enhances PA01 tolerance
under these conditions in comparison to an yfiBNR mutant strain.
YfiR misfolding thus potentially represents a second mode of
YfiBNR sensory input, and suggests a role for the system in the
response to reducing environments. For example, it is conceivable
that the Yfi system is able to sense anoxic conditions through the
redox sensitive cysteines of YfiR and by that induce biofilm in the
absence of oxygen. The option to employ YfiR directly as a signal
input domain, either as a cysteine-dependent redox sensor or
through another as-yet-undiscovered mechanism, predicts the
existence of Yfi-like signaling systems in which YfiB is missing.
This is indeed the case. While complete yfiBNR systems are
widespread in the gamma- and beta-proteobacteria (with the
alpha-proteobacteria Sphingopyxis representing the only genus
external to these two classes) many YfiNR pairs lacking an YfiB
component are found in species both closely related and widely
divergent from P. aeruginosa. In particular, species in the Salmonella
and Dickeya genera have conserved YfiN and YfiR homologs, but
lack YfiB. Given the positions of Salmonella and Dickeya in the
YfiBNR lineage tree it seems likely that these genera may once
have had functional YfiB homologs, but have since lost them.
Evolution has not only modulated the input side of the YfiBNR
system, the output domains of more divergent Yfi homologs are
also variable. Careful in silico analysis identified histidine kinases,
GGDEF/EAL pairs and MCP domains in place of the YfiN
GGDEF domain. Despite this diversity of signaling outputs, the
residues predicted for YfiN-YfiR interaction are well conserved.
This led us to hypothesize that this YfiR-YfiN [PAS/HAMP] core
may be a more ancient signaling module, which in evolution has
been connected in a modular fashion to different output and
additional input domains. This core module, characterized by the
binding of a periplasmic repressor to the PAS-like domain of a
transmembrane signal transduction system, represents a novel and
apparently widespread signaling motif in bacteria. The YfiN-YfiR
interaction shares some striking characteristics with the LapD-
LapG system of Pseudomonas fluorescens [68,69,70] and Pseudomonas
putida [71]. The unique periplasmic domain of the c-di-GMP
signaling protein LapD sequesters the periplasmic protease LapG
when c-di-GMP is present, preventing it from cleaving the adhesin
LapA. Periplasmic protein interaction systems such as LapAG and
YfiBNR may well be representatives of a broader regulatory
principle in bacterial signaling.
The mutational analysis described in this study demonstrated
several possible genetic routes to yfi-mediated SCV formation. In
addition to loss-of-function mutations in yfiR, mutations that
mimic an active conformation may arise at specific locations in the
PAS, HAMP or transmembrane regions of YfiN, or towards the
N-terminus of YfiB. When analyzing the yfi operons of clinical
SCVs we identified several that contained either an inactivating
mutation in yfiR or an activating mutation in yfiN, arguing that the
Yfi signal transduction system is under strong positive selection in
the lung environment. Apparently, one route to generate SCVs in
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vivo is by an increase of c-di-GMP through mutations that activate
or de-repress a diguanylate cyclase. Consistent with this, the
methylesterase wspF, whose disruption induces c-di-GMP depen-
dent SCV formation in vitro [72], was shown to be mutated in a P.
aeruginosa strain following adaptation to the CF lung [2]. Similarly,
Rau et al. have identified a persistent CF isolate in which the
GGDEF/EAL protein MorA is strongly upregulated [73].
Furthermore, we find that in a large fraction of P. aeruginosa SCVs
isolated from CF lungs the characteristic morphotype can be
alleviated or reversed to a more rapidly growing smooth
phenotype by the expression of a phosphodiesterase (Jaeger, Bos
and Jenal, unpublished). Of the five SCV-inducing mutations
isolated in the yfi system, four were gain of function mutations in
YfiN, with only one loss-of-function mutation found in YfiR. This
is surprising, as one expects loss-of-function mutations in yfiR to
occur more frequently than activating mutations in yfiN. These
findings seem to suggest that the strongest Yfi-mediated SCVs,
produced when YfiR is absent and YfiN is fully active, are
disfavored in the CF lung compared with weaker morphotypes
produced by activated YfiN alleles. It is possible that YfiR has a
supplementary role in cell signaling and that loss-of-function
mutations in the yfiR gene incur an unforeseen fitness cost in the
human host. Alternatively, activating mutations in yfiN might be
favored because they allow the system to retain some degree of
flexibility, where a secondary genetic or regulatory increase in
YfiR activity could override the activating effect of the original
mutation in yfiN. Careful analysis of selected clinical SCVs indeed
provided evidence for consecutive rounds of mutations affecting
the yfi system. The finding that some clinical strains contained
both gain- and loss-of function mutations in yfiN strongly suggested
that SCVs can function as an environmental pool for the
generation of new smooth morphotypes. Apparently, SCVs do
not represent a dead end in the dynamic and heterogeneous
environment of chronically infected CF airways and may be
continuously favored and disfavored over time and/or different
lung environments. In this way the behavior of clinical P. aeruginosa
SCVs reflects that of P. fluorescens cultured in vitro [36], where
sequential gain and loss of function mutations arose in c-di-GMP
related systems (including Yfi/Aws), in response to environmental
changes. The variable fitness of SCVs might well be explained by
the characteristic slow growth of these morphotypes [11], which
may contribute substantially to persistence under very stringent in
vivo conditions but pose dramatic costs under conditions that favor
rapid growth. E.g. antibiotic treatment regimens or other insults
that alter the fragile homeostasis between airway pathogens and
local host defenses [74] might favor selection for persistence traits,
while in the absence of such conditions rapidly growing sub-types
might have a considerable advantage. Continuous adaptation of
the c-di-GMP network could facilitate these physiological adjust-
ments and thereby contribute to the in vivo fitness of P. aeruginosa
during chronic lung infections.
CF patients are permanently colonized by P. aeruginosa with the
same bacterial lineage persisting continuously in the lungs for years
or even decades and without being eradicated by chemotherapy.
The development of effective treatments rests on a detailed
understanding of how bacteria adapt to the airway and resist host
defenses and antibiotics. Several reports have indicated a striking
correlation between mutagenesis and persistence of P. aeruginosa in
CF lungs [2,75,76,77]. Smith et al. [2] have reported that during
chronic infection P. aeruginosa adapts by loss-of-function mutations
that remove virulence factors required for the acute phase of
infection. But while this study outlines factors that are disadvan-
tageous in chronic infection, it does not provide information about
what is needed to enhance fitness in CF airways and sustain the
clonal expansion of P. aeruginosa during chronic infection. Alleles
causing (often subtle) positive changes in protein function are more
difficult to identify and rationalize than loss-of-function mutations
and often require experimental input to be validated. E.g., the
identification and elucidation of the yfi gain-of-function alleles in
clinical isolates was critically dependent on the mechanistic
understanding that could only be provided by a thorough
molecular analysis of the pathway. Based on these studies we
propose that rapid evolution of diguanylate cyclases and possibly
other components of the c-di-GMP network contributes to the
remarkable flexibility and degree of persistence of P. aeruginosa cells
in CF lungs. A thorough understanding of the underlying
physiological processes is mandatory to predict, delineate and
interfere with these in vivo selection processes.
Materials and Methods
Ethics statement
The clinical Pseudomonas aeruginosa strains used for this research
were cultured from patient samples collected for routine micro-
biological testing at the University Children’s Hospital, Basel or
the Medical Microbiological Department of the Hannover
Medical School. Subculturing and analysis of bacteria was
performed anonymously. No additional procedures were carried
out on the patients. Cultures were sampled following regular
procedures with written informed consent, in agreement with the
guidelines of the ‘‘Ethikkommission beider Basel EKBB’’ or with
approval by the Ethical Board of the Hannover Medical School.
Strains and growth conditions
Strains and plasmids used in this study are listed in Table S1.
Primers are listed in Table S2. Unless otherwise stated, all P.
aeruginosa and E. coli strains were grown at 37uC in Luria Bertani
(LB) medium [78], solidified with 1.3% agar where appropriate.
For P. aeruginosa, gentamycin was used at 30 mg/ml (E. coli 20 mg/
ml), carbenicillin at 100 mg/ml and tetracycline at 50/100 mg/ml
(E. coli 12.5 mg/ml). For E. coli, ampicillin was used at 100 mg/ml.
Congo Red dye was added to a final concentration 0.04%. For
inducible plasmids, IPTG was added to a final concentration 0.2
or 1 mM and arabinose to 0.2% as appropriate.
Molecular biology procedures
Cloning was carried out in accordance with standard molecular
biology techniques. To produce a chromosomal flag-tagged copy
of yfiN E. coli DY330 [79] was transformed with plasmid pMR20-
yfiBNR [11]. The PCR fragment amplified with primers A and B
from plasmid pSUB11 [80] were then used to produce a C-
terminal yfiN fusion in pMR20 by the method described by Yu
et al. [79]. The resulting yfiN-flag fragment was then ligated between
the HindIII and BamHI sites of pUC18T-mini-Tn7T-Gm [81].
The yfiR screening plasmid pMR-yfiR-flag was constructed by
replacement of the lac-promoter/lacI fragment of pMR20-yfiR-M2
[11] with a chloramphenicol cassette amplified using primers C
and D, according to the method of Yu et al. [79]. The
chloramphenicol gene was then excised by Flp-mediated excision
using the plasmid pFLP2 [82]. To produce the yfiN screening
plasmid pGm-yfiprom-N, the tetracycline resistance cassette was
excised from pME6032 [83] between BamHI and XbaI, and
replaced with the aacCI gentamycin resistance cassette, amplified
with primers E and F from pBBR-MCS5 [84]. The lac-promoter/
lacI fragment was then excised between EcoRI and BamHI and the
EcoRI site was blunted with klenow polymerase. The yfiN fragment
was amplified with primers G and H from PA01 DyfiR [11] and
ligated between BamHI and the blunt site.
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The three pME-yfiB-PG- variants were constructed by ligation
of yfiB fragments (amplified with primers I and U, from the
appropriate pME6032-yfiB gain-of-function plasmids) between the
EcoRI and AscI sites of pME6032-yfiB [11]. To make the yfiB-LA-
constructs, yfiR was amplified with primers V and P, and yfiB with
primers W and J from genomic DNA (or pME-yfiB-PG- as
appropriate). The MfeI-PstI yfiR fragment and the PstI-BamHI yfiB
fragments were then ligated between the EcoRI and BglII sites of
pME6032. The long/short yfiB inserts were produced by SOE-
PCR using primers AH/AI together with primers X/Y or Z/AA,
and ligated into pME6032 between EcoRI and BglII. To produce
pME-araC-dsbA, the dsbA fragment amplified with primers K and
L from PA01 genomic DNA was ligated between the EcoRI-KpnI
sites of pME-araC [11,83]. To make pME-araC-yfiR the PCR
product amplified with primers V and P was cut with MfeI-BamHI
and ligated between the EcoRI-BglII sites of pME-araC.
To produce pTn7-yfiBN20265-R, the yfiBNR operon of
SCV20265 was amplified using primers G and J and ligated
between the HindIII and BamHI sites of pUC18T-mini-Tn7T-Gm.
The G173D and D255-7 variants were produced by digesting
yfiBNR PCR products from SCV20265 and WT PA01 templates
at a PstI site midway between the two mutations, then ligating both
inserts between BamHI and HindIII as above. Clinical yfiN/yfiR
mutant alleles were produced by SOE PCR using primers AR/AS
and AJ-AQ for yfiN, and AZ/BA and AT-AY for yfiR,
respectively. Inserts were then ligated into NcoI-BamHI-cut
pME6032-Gm or HindIII-BamHI-cut pMR-yfiR-flag respectively.
XL1-red mutagenesis
Mutator strain E. coli XL1-red (Stratagene) was transformed
with the plasmid pGm-yfiprom-N according to the method of
Chung et al. [85] and plated onto LB gentamycin plates. After
overnight growth at 37uC the transformant colonies were pooled
and plasmid DNA extracted. This pooled DNA was then used to
transform the screening strain DyfiNR pMR-yfiR-flag. Samples
were plated onto LB plates containing gentamycin, tetracycline
and Congo Red and transformants exhibiting an SCV phenotype
were selected as potentially carrying activated YfiN alleles. These
SCVs were restreaked onto fresh plates and the yfiN gene amplified
in each case via colony PCR, using primers G and H. Mutations in
yfiN were then identified by sequencing.
Screening by error-prone PCR
Plasmids pME6032-yfiB [11] and pMR-yfiR-flag were used as
templates for error-prone PCR reactions following the method
described in [86], and consisting of 2 min 94uC, then 25 cycles of
45 sec 94uC, 45 sec 55uC and 90 sec 72uC, before a final
extension for 10 min at 72uC. Each 50 ml reaction contained
0.2 mM dNTPs, Taq polymerase buffer, 5U Taq polymerase,
0.3 mM forward and reverse primers (I/J and G/P), 1.0 ml
template DNA and 0.5–1.0 ml mutagenesis buffer (4 mM dTTP,
4 mM dCTP, 27.5 mM MgCl2, and 2.5 mM MnCl2). Pools of
mutated yfiR and yfiB fragments were then ligated into their parent
vectors between HindIII - BamHI, and EcoRI - BglII respectively.
To screen for yfiB mutants, DyfiBNR Tn7::yfiNR [11] was
transformed with pooled pME6032-yfiB and SCV transformants
were isolated from selective LB plates. Mutations in yfiB were
identified by sequencing. For yfiR mutants, DyfiNR was trans-
formed with pooled pMR-yfiR-flag and the resulting transformant
colonies used to make electrocompetent cells. Plasmids carrying
the 20 activated yfiN alleles were extracted and purified, then used
to transform the DyfiNR pMR-yfiR-flag pooled cells. Transformants
were screened on selective LB plates for smooth colonies
containing potential dominant YfiR alleles. To eliminate suppres-
sor mutations in the screening strain, pMR-yfiR-flag DNA was
extracted from smooth strains and used to transform DyfiNR
containing the relevant activated-yfiN plasmid. The yfiR alleles
present in those strains that displayed a smooth morphotype at this
stage were analyzed by sequencing.
Transduction with phage E79tv2
The E79tv2 [87] transducing lysate for the Tn5::wspR strain was
prepared and used according to the protocol described in our
previous work [11].
Deletion of the dsbA gene
The strains PA01 DdsbA and DyfiBNR DdsbA were constructed
via an adaptation of the protocol described elsewhere [88]. Briefly,
the dsbA deletion construct was produced by SOE-PCR using
primers Q-T, and contained homologous flanking regions to the
target gene. This construct was ligated into pME3087 between
HindIII-BamHI. The resulting vector was then used to delete dsbA
by two-step allelic exchange. Following transformation into the
target strain, single crossovers were selected on tetracycline and
restreaked. Cultures from single crossovers were grown overnight
in LB medium, and diluted 1:100 into fresh medium. After
2 hours, 20 mg/ml tetracycline was added to inhibit the growth of
cells that had lost the tetracycline cassette. After a further hour of
growth, 2000 mg/ml carbenicillin was added to select against
growing bacteria. Cultures were grown for a further 4–6 hours,
before cells were harvested by centrifugation, washed once in LB
and used to inoculate an overnight culture. This counter-selection
was done twice, before plating of a dilution series of the final
samples onto LB agar. Individual colonies were patched onto LB
plates 6 tetracycline, tetracycline sensitive colonies were tested for
deletion of dsbA by colony PCR.
Attachment assays
Assays to test the different alleles of the yfiBNR system were
performed as described in [11,89]. Briefly, 96 well plates
containing 150/200 ml LB medium/well were inoculated with
single colonies using sterile toothpicks, and incubated overnight at
37uC without shaking. Plates were washed three times with
distilled water. The attached cell material was then stained with
0.1% Crystal Violet solution (5% methanol, 5% isopropanol)
before further washing to remove excess dye. Crystal Violet was
re-dissolved in 20% acetic acid solution and absorbance measured
at 600 nm. Assays were performed with 6 wells/strain and
repeated independently for each experiment.
The attachment assays for phenotypic testing of stress condi-
tions were performed with the following modifications. Strains
were grown on LB plates O/N at 37uC then scraped from the
plates and diluted in the appropriate medium used for the
experiment. 96 well plates containing 200 ml medium/well were
inoculated with the diluted bacterial suspension to a final OD600 of
0.001, plates were incubated overnight at 37uC without shaking.
Envelope stress was tested on M9 minimal medium (47.6 mM
Na2HPO4, 22 mM KH2PO4, 8.6 mM NaCl, 18.6 mM NH4Cl,
2 mM MgSO4, 0.1 mM CaCl2, 0.03 mM Fe-III-citrate) contain-
ing 10 mM Na-succinate as a carbon and energy source and 0.01–
0.25% sodium dodecyl sulfate (SDS) [90] and with osmotic stress
minimal medium M63 (100 mM KH2PO4, 15 mM (NH4)2SO4,
2 mM FeSO4, 1 mM MgSO4, 0.001 mg/ml Thiamin) [78] with
20 mM Na-succinate, 0.2% Glucose and 0.01–0.4 M NaCl [91].
Reducing conditions were tested on MHB (Mueller-Hinton broth,
cation adjusted, Becton Dickinson) containing 1.25–20 mM
Dithiothreitol (DTT). Assays were performed at least 3 times
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independently with 12 wells/condition tested, shown is the mean
of all experiments.
Immunoblot analysis
Samples were separated on 15% Tris-HCl gels and blotted onto
polyvinylidene difluoride (PVDF) membranes (Millipore). Mem-
branes were incubated overnight in blocking solution (16 PBS
pH 7.4, 0.01% Tween20, 5% milk powder), after which proteins
were detected with 1/5000 (a-M2, a-YfiB) or 1/2000 (a-YfiN)
specific antiserum and 1/10,000 rabbit anti-mouse (a-M2) or
swine anti-rabbit (a-YfiB, a-YfiN) secondary antibody (DakoCy-
tomation). Bound antibodies were visualized using ECL chemilu-
minescent detection reagent (Perkin-Elmer). Samples were nor-
malized following comparison of optical density for the initial cell
samples in each case.
Co-immunoprecipitation
PA01 overnight cultures (or colonies scraped from agar plates,
in the case of SCV strains) were pelleted by centrifugation and re-
suspended in ice-cold IP buffer (20 mM HEPES pH 7.4,
100 mM NaCl, 1 mM EDTA, 1.0% v/v Triton X-100, protease
inhibitor), then incubated at 4uC with end-over-end agitation for
6 hours. All subsequent steps were carried out on ice. Samples
were centrifuged (15,000 g, 20 min, 4uC), and the supernatant
was removed and incubated with 20 mg/ml protein-A agarose
beads at 4uC with end-over-end agitation for 30 min to remove
non-specifically binding proteins. The samples were then
centrifuged (3,000 g, 1 min 4uC) to pellet the beads, an aliquot
of the supernatant was taken for analysis, and the remaining
supernatant was incubated overnight with 20 mg/ml ANTI-flag
M2 affinity gel (Sigma) at 4uC with end-over-end agitation.
Samples were pelleted by centrifugation (3,000 g, 1 min 4uC), the
supernatant was discarded and the beads re-suspended in 1.0 ml
ice-cold IP buffer. This wash step was repeated between 3 and 5
times. The beads were then re-suspended in SDS sample buffer,
boiled for 10 minutes at 95uC and pelleted by centrifugation.
Interacting proteins in the supernatant were detected by
immunoblotting.
Membrane fractionation
The fractionation protocol was adapted from the method
described in [92]. 50 ml overnight cultures of PA01 strains were
pelleted by centrifugation, washed once with Tris buffer (30 mM
Tris pH 8.0), and re-suspended in 6.0 ml Tris buffer containing
20% w/v sucrose, 1 mg DNase, 1 mg RNase, and 2 mg lysozyme.
Samples were incubated for 20 minutes at room temperature, then
lysed by French Press, diluted to 10% sucrose with Tris buffer and
centrifuged to remove cell debris (3,500 g, 15 min, 4uC). Protease
inhibitors were added at this stage as a precaution. The soluble
and membrane fractions were then separated by ultracentrifuga-
tion (160,000 g, 105 min, 4uC) on a Tris buffered 15%/70%
sucrose gradient. The membrane fraction was recovered from the
15%–70% interface and diluted to about 30% with Tris buffer,
before loading onto a Tris buffered, sucrose step-gradient (steps
contained 70, 64, 58 and 52% sucrose). The samples were then
ultracentrifuged for 18 hours (160,000 g, 4uC) to separate inner
and outer membranes. The four bands visible after ultracentrifu-
gation were recovered, diluted in 1–2 volumes Tris buffer and
pelleted (15,000 g, 35 min, 4uC), before being re-suspended in
Tris buffer and analyzed by immunoblotting. Western blot
samples were normalized according to the total protein content
of the different fractions, determined with a Protein assay kit
(BioRad).
Quantitation of cyclic-di-GMP levels
C-di-GMP levels of clinical strains were measured by liquid
chromatography-tandem mass spectrometry after [93]. The
protein content of each pellet (post-extraction) was determined
with a Protein Assay kit (BioRad). Measurements were in triplicate
and values expressed as pmol c-di-GMP/mg protein.
Sequence analysis of clinical SCV strains
In total 45 auto-aggregative SCV strains isolated from the
sputum of CF patients were grouped in three pools of 15 strains.
Each strain was cultivated individually in 20 ml LB medium at
37uC and shaking at 180 rpm to an OD600 of 1.0. 1 ml of each
culture was harvested by centrifugation (8000 rpm, 1 minute, 4uC)
and the cell pellet was washed once with 1 ml sterile deionized
water. Pellets were resuspended in sterile deionized water, pooled
at equal amounts and DNA was isolated from the pooled cell
suspensions using the DNeasy Blood & Tissue Kit (Qiagen)
according to the manufacturer’s instructions.
DNA samples were further prepared and sequenced using
76 bp paired end sequencing on a Genome Analyzer II-x
(Illumina). Libraries of 250 bp prepared according the manufac-
turer’s instructions ‘‘Preparing Samples for Paired-End-Sequenc-
ing’’. Cluster generation was performed using the Illumina cluster
station, sequencing for read 1 and read 2 on the Genome Analyzer
followed a standard protocol. The fluorescent images were
processed to sequences using the Genome Analyzer Pipeline
Analysis software 1.6 (Illumina).
The sequence reads were quality-trimmed using the perl script
Trim.pl by Nik Joshi (obtained from http://wiki.bioinformatics.
ucdavis.edu/index.php/Trim.pl) in the ‘‘windowed adaptive
trimming’’ mode, removing any sequence with a quality score
,10. Detection of single nucleotide polymorphisms (SNPs) was
performed with the MAQ software [Li et al, 2008, Genome Res
18:1851] using a perl script that calculates the frequencies of SNPs
in pooled sequences [Holt et al., 2009, Bioinformatics 25:2074].
Identification of YfiBNR homologs in other systems
An initial set of genomes displaying synteny conservation among
homologs to PA1119 (GenBank:15596316), PA1120 (Gen-
Bank:15596317) and PA1121 (GenBank:15596318) from Pseudo-
monas aeruginosa PAO1 (GenBank:AE004091) was manually
defined. Synteny conservation was assessed for complete microbial
genomes of the RefSeq database on the MAGE database server
[94]. The three sets of protein sequences corresponding to each
homologous group were aligned with CLUSTAL W (default
settings) [95]. Hidden Markov Models were then computed with
HMMER.3 (http://hmmer.org/). Models were calibrated and
searched against a local copy of the microbial complete genome
database (NCBI) with HMMER.3. A series of Perl scripts were
used to sort the outputs and to count occurrences of complete or
partial systems as described in Figure 8. Occurrences of homologs
(E-value,1024) were then reported on an illustrative phylogenetic
tree based on 16S rRNA sequences from the ribosomal database
project (RDP, http://rdp.cme.msu.edu/index.jsp) [96]. All se-
quences were .1200 nucleotides and tagged as ‘‘good quality’’
according to RDP. Type strains and isolated samples were
preferred. At least two sequences/genus were downloaded as
alignment files from RDP. Consensus was inferred using
EMBOSS (http://www.sanger.ac.uk/ Software/EMBOSS). Ge-
nus consensuses were aligned with CLUSTAL W (default settings)
and phylogenetic analyses were conducted in MEGA4 [97].
Evolutionary history was inferred using the UPGMA method [98],
and evolutionary distances were computed using the Maximum
Composite Likelihood method. All positions containing gaps and
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missing data were eliminated (Complete deletion option), leaving a
total of 1143 positions in the final dataset.
Molecular models of the YfiBNR proteins were produced using
HHPRED (http://toolkit.tuebingen.mpg.de/hhpred) and visual-
ized with PYMOL (http://pymol.org/). Models were based on the
following structures: YfiN PAS: 1p0z_A, YfiN HAMP: 3lnr_A,
YfiR: 2iss_D, 2ywj_A, 3lft_A, 3dfu_A, 2abw_A, 2ioj_A, and
1yqg_A, YfiB: 2kls_A and 2ldt_A. Sequence conservation plots
were visualized using WebLogo 3 [99].
Supporting Information
Figure S1 Localization and stability of YfiR. A) Outer
Membrane localization of YfiR-flag. Immunoblot of fractionated
membrane samples stained with M2 antisera. The panel shows the
soluble and the outer membrane fractions for DyfiBNR, DyfiNR and
DyfiBNR Tn7::yfiNR harboring pMR-yfiR-flag (p-yfiR). B) Stability
of YfiR-flag in whole cell lysate. Immunoblot of DyfiR, DyfiNR
and DyfiBNR with yfiR-flag inserted into the att-Tn7 site, and one
time point with the strains over expressing YfiR (DyfiBNR,
DyfiNR and DyfiBNR Tn7::yfiNR harboring pMR-yfiR-flag (p-
yfiR)). ‘t’ indicates different time points (hours post inoculation);
‘O/N’ overnight incubation.
(PDF)
Figure S2 Colony morphologies with activated YfiN
alleles. A) Colony morphologies of DyfiNR pGm-yfiprom-N,
pMR-yfiR-flag strains with the point mutants indicated present in
YfiN. ‘pyfiR pyfiN’ denotes the wild-type control; ‘pyfiN’ denotes a
strain containing pGm-yfiprom-N only. B) Colony morphologies for
cross-complementation strains. The YfiN (bold) and YfiR (italic)
mutant alleles present are shown in each case.
(TIF)
Figure S3 Attachment of Yfi mutants in response to the
presence of SDS or changes in osmolarity. A) Attachment
on M9 medium with 20 mM Na-succinate and increasing
concentrations of SDS is shown relative to PA01. B) Attachment
with low and high osmolarity, on M63 medium with 20 mM Na-
succinate, 0.2% glucose, and increasing concentrations of NaCl is
shown relative to PA01. 50% and 75% indicate dilutions of the
medium with distilled water. DBNR indicates DyfiBNR and DB
indicates DyfiBNR Tn7::yfiNR. Bars represent the level of absolute
attachment and curves represent optical density (OD) of total cells
with standard errors.
(PDF)
Figure S4 Attachment of clinical iosolates in the pres-
ence of a phosphodiesterase. The effect of a PDE, in Clin110
and Clin163, on attachment is shown relative to strains expressing
an active site mutant (PDE*). The PDE (PA5295) and the active
site mutant are expressed from a vanillate inducible vector (pBV-
PA5295 and pBV-PA5295E328A respectively).
(PDF)
Figure S5 Sequence conservation across distant YfiN/
YfiR homologs. Sequence alignments for YfiR (residues 55–190)
and the YfiN PAS domain (residues 61–115), across PA01 and five
distant homologs. The five species whose yfiNR genes were
compared were: Opitutus terrae PB90-1, Acidobacteria bacterium
Ellin345, Geobacter sp. M21, Rhodothermus marinus DSM 4252, and
Desulfobacterium autotrophicum HRM2. Fully conserved residues are
marked with an asterisk (*), similarities are marked with (:) or (.).
Putative hydrophobic binding site residues are enclosed in black
boxes. Residues are colored according to the chemical nature of
their side chains.
(PDF)
Table S1 Bacterial strains and plasmids used in this
study.
(PDF)
Table S2 Primers used in this study.
(PDF)
Table S3 Single nucleotide polymorphism (SNP) posi-
tions in the sequences of clinical SCVs, compared to P.
aeruginosa PA01.
(PDF)
Table S4 Identification of YfiBNR homologs in other
systems.
(PDF)
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